Common Contracts
4 similar Securities Agreement contracts by Antigenics Inc /De/, Inventergy Global, Inc., Marathon Patent Group, Inc.
ContractSecurities Agreement • May 15th, 2015 • Inventergy Global, Inc. • Telephone communications (no radiotelephone)
NEITHER THESE SECURITIES NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN FROM AN ACCREDITED INVESTOR SECURED BY SUCH SECURITIES.
MARATHON PATENT GROUP, INC. WARRANTSecurities Agreement • February 3rd, 2015 • Marathon Patent Group, Inc. • Patent owners & lessors
Marathon Patent Group, Inc., a Nevada corporation (the “Company”), hereby certifies that, for value received, DBD Credit Funding LLC or its registered assigns (including permitted transferees, the “Holder”), as registered owner of this warrant (the “Warrant”), is entitled to purchase from the Company up to a total of 100,000 shares (as adjusted from time to time as provided in Section 9) of Common Stock (as defined below), at an exercise price a price per share equal to the lesser of (i) the closing bid price per share on the Trading Day immediately preceding the date hereof and (ii) the average of the closing bid price per share for the last thirty previous Trading Days preceding the date hereof (as adjusted from time to time as provided in Section 9, the “Exercise Price”), at any time and from time to time from and after the date hereof (the “Initial Exercise Date”) to and including the fifth (5th) anniversary of the date hereof (the “Expiration Date”), and subject to the following t
ANTIGENICS INC WARRANTSecurities Agreement • April 10th, 2008 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
Antigenics Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received, or its registered assigns (including permitted transferees, the “Holder”), as registered owner of this warrant (the “Warrant”), is entitled to purchase from the Company up to a total of shares (as adjusted from time to time as provided in Section 9) of Common Stock (as defined below), at an exercise price equal to $3.75 per share (as adjusted from time to time as provided in Section 9, the “Exercise Price”), at any time and from time to time from and after October10, 2008 (the “Initial Exercise Date”) to and including April 9, 2013 (the “Expiration Date”), and subject to the following terms and conditions.
ANTIGENICS INC WARRANTSecurities Agreement • January 11th, 2008 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
Antigenics Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received, or its registered assigns (including permitted transferees, the “Holder”), as registered owner of this warrant (the “Warrant”), is entitled to purchase from the Company up to a total of shares (as adjusted from time to time as provided in Section 9) of Common Stock (as defined below), at an exercise price equal to $3.00 per share (as adjusted from time to time as provided in Section 9, the “Exercise Price”), at any time and from time to time from and after July 9, 2008 (the “Initial Exercise Date”) to and including January 9, 2018 (the “Expiration Date”), and subject to the following terms and conditions.
